Triple-negative breast cancer: 2025 consensus guidelines
Authors:
- Eduardo Carvalho PessoaEPEduardo Carvalho Pessoa
- Fabio BagnoliFBFabio Bagnoli
- Marcelo MadeiraMMMarcelo Madeira
- Joaquim Teodoro AraujoJAJoaquim Teodoro Araujo
- Giuliano Mendes ToselloGTGiuliano Mendes Tosello
- Fabricio BrenelliFBFabricio Brenelli
- Beatriz Baaklini GeronymoBGBeatriz Baaklini Geronymo
- Daniel de Araujo ButtrosDBDaniel de Araujo Buttros
- Felipe ZerwesFZFelipe Zerwes
- Marcelo AntoniniMAMarcelo Antonini
- Daniel Luiz GimenesDGDaniel Luiz Gimenes
- Silvio Eduardo BrombergSBSilvio Eduardo Bromberg
Open Access
Abstract
Objective: To disseminate the clinical guidelines established at the 2025 São Paulo Breast Diseases Symposium regarding the management of early triple-negative breast cancer (TNBC). Methods: The symposium convened 110 panelists, predominantly mastologists from São Paulo (101 mastologists, of which 94 from São Paulo and 7 from other regions: 1 from Bahia [Northeast], 2 from Rio Grande do Sul [South], 1 from Minas Gerais, 2 from Goiânia [central region], and 1 from Fortaleza [Northeast]), plus 6 oncologists, 2 pathologists, and 1 radiotherapist (all from São Paulo). Four priority topics were presented in evidence-based lectures, followed by technical discussions and anonymous electronic voting by all panelists. Consensus was defined as ≥75% agreement. Results: Voting showed 40% support for T1cN0 as the cutoff for upfront surgery, 16% for T2N0, but no consensus was reached. Consensus was achieved for using tumor-infiltrating lymphocytes (TILs) as an adjunct biomarker to guide initial systemic treatment (83%) and for sentinel lymph node biopsy (SLNB) as standard following neoadjuvant chemotherapy (NACT) (78%). Post-mastectomy radiotherapy was recommended even after pathological complete response (pCR) by 72%, though without consensus. Conclusions: The 2025 São Paulo Breast Diseases Symposium established guidelines for early TNBC management. Consensus was achieved for using TILs as an adjunct biomarker (83%) and SLNB as standard post-NACT (78%), while upfront surgery cutoff (40% for T1cN0) and radiotherapy omission post-pCR (72%) did not reach consensus, reflecting heterogeneous practices and the need for individualized approaches and further research.Keywords
This publication has 27 references indexed in Scilit:
- Early-Stage Breast Cancer: A Critical Review of Current and Emerging PracticeInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2024
- Tumor-Infiltrating Lymphocytes in Triple-Negative Breast CancerJAMA, 2024
- Prognostic value of histopathologic traits independent of stromal tumor-infiltrating lymphocyte levels in chemotherapy-naïve patients with triple-negative breast cancerESMO Open, 2024
- Benefit of adjuvant chemotherapy in node-negative T1a versus T1b and T1c triple-negative breast cancerBreast Cancer Research and Treatment, 2022
- 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)Annals of Oncology, 2020
- Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast CancerJAMA, 2013
- Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort studyThe Lancet Oncology, 2013
- Local-Regional Recurrence With and Without Radiation Therapy After Neoadjuvant Chemotherapy and Mastectomy for Clinically Staged T3N0 Breast CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trialThe Lancet Oncology, 2010
- Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancerCancer Chemotherapy and Pharmacology, 1978